Agios Pharmaceuticals (AGIO) Change in Receivables (2015 - 2026)

Agios Pharmaceuticals (AGIO) has 8 years of Change in Receivables data on file, last reported at $4.0 million in Q2 2026.

• Quarterly Change in Receivables rose 142.39% year-over-year to $4.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.1 million (up 1135.78% YoY) and the FY2025 annual result came in at $6.5 million, up 397.92% from the prior year.
• Change in Receivables fell to $4.0 million in Q2 2026, from $5.6 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $5.6 million in Q1 2026 to a low of -$1.1 million in Q3 2023.
• A 5-year average of $1.1 million and a median of $506500.0 in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2023 — Change in Receivables plunged 588.64% — and 2026, when it jumped 826.14%.
• Tracing AGIO's Change in Receivables over 5 years: stood at $388000.0 in 2022, then jumped by 321.13% to $1.6 million in 2023, then slumped by 39.35% to $991000.0 in 2024, then soared by 459.84% to $5.5 million in 2025, then declined by 28.26% to $4.0 million in 2026.
• The last three Change in Receivables figures came in at $4.0 million (Q2 2026), $5.6 million (Q1 2026), and $5.5 million (Q4 2025), per Business Quant data.